The most comprehensive HRD tumor test to guide PARP inhibitor treatment decisions.
Homologous Recombination Deficiency (HRD) is present in approximately 48% of ovarian cancer tumors1 and is associated with sensitivity to PARPi therapy.2
International guidelines include recommendations for HRD testing for ovarian cancer.2,3
- The Cancer Genome Atlas. Nature 2011
- Miller et al. Annals of Oncology (2020) in press: https://doi.org/10.1016/j.annonc.2020.08.2102
- Tew et al. JCO (2020) in press: https://ascopubs.org/doi/pdf/10.1200/JCO.20.01924
What is Myriad myChoice® CDx PLUS?
myChoice® CDx PLUS is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer, fallopian tube and primary peritoneal cancer. This CE marked test helps to identify ovarian cancer patients with a Homologous Recombination Deficiency who might be considered for treatment with PARPi therapy.
HRD status is determined using two individual methods: BRCA1 & BRCA2 status that includes sequence variants and large rearrangements and Genomic Instability Status encompassing Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI) and Large-Scale State Transitions (LST) measured across the entire genome. It is the only commercially available tumor test that has been designed to detect these 3 biomarkers of genomic instability. In addition, the test assesses both pathogenic variants and pathogenic large rearrangements which account for ~5% of all BRCA mutations in ovarian cancer.